CoVITEST: A Fast and Reliable Method to Monitor Anti-SARS-CoV-2 Specific T Cells From Whole BloodCoVITEST: 전혈에서 Anti-SARS-CoV-2 특정 T 세포를 모니터링하는 빠르고 신뢰할 수 있는 방법Article Published on 2022-07-052022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] adjust antibodies Antibody detection automated Blood blood test can be used Cellular immune response cellular immunity cellular response comparable complex convalescent COVID-19 demonstrated determine diagnostic Donor ELISPOT Evidence explained gold gold standard healthy help house humoral immune response humoral immune responses IFN-γ IFN-γ ELISPOT immune protection immune responses Immune status IMPROVE individual less MONITOR pandemic Patient protocol Reinfection SARS-CoV-2 side simple Specific Support T cell T cells Test therapeutic approaches vulnerable patient vulnerable patients weakened immune system [DOI] 10.3389/fimmu.2022.848586 PMC 바로가기 [Article Type] Article
Immune Responses Against SARS-CoV-2 WT and Delta Variant in Elderly BNT162b2 Vaccinees노인 BNT162b2 백신의 SARS-CoV-2 WT 및 Delta 변이체에 대한 면역 반응Article Published on 2022-06-272022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, [키워드] Against age Age-dependent immune responses after BNT162b2 analyzed antibody Antibody titer Antibody titers B.1.617.2 Blood BNT162b2 booster cellular cohorts coronavirus COVID-19 Delta delta variant elderly ELISPOT group groups highlighting humoral immune response IFNγ IgG titers immune response immune responses Immunoglobulin Immunoglobulin G mononuclear cell mononuclear cells neutralization ability neutralization activities neutralization activity neutralization titer neutralization titers Neutralizing Neutralizing activity Neutralizing antibodies nursing homes overcome pandemic participant peripheral Peripheral blood Peripheral blood mononuclear cells resident response rising SARS-CoV-2 SARS-CoV-2 delta SARS-CoV-2 spike protein SARS-CoV-2 vaccination SARS-CoV-2 WT second vaccination significantly increased specific antibodies Spike protein syndrome T cell T cell immunity T cell response vaccination vaccine dose vaccinee vaccinees Vaccines variants variants of concern variants of concern (VOCs) variants of SARS-CoV-2 Virus neutralization VOCs wild-type [DOI] 10.3389/fimmu.2022.868361 PMC 바로가기 [Article Type] Article
Specific Antibody and the T-Cell Response Elicited by BNT162b2 Boosting After Two ChAdOx1 nCoV-19 in Common Variable Immunodeficiency공통 가변성 면역 결핍증에서 2개의 ChAdOx1 nCoV-19 후 BNT162b2 부스팅에 의해 유도된 특정 항체 및 T-세포 반응Article Published on 2022-06-172022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 바이오마커, 진단, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 anti-SARS-CoV-2 anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 immunoglobulin Anti-spike antibody autologous BNT162b2 BNT162b2 vaccine booster vaccination CD19 CD19+ CD3+ CD3+CD4+ CD3+CD8+ CD4+ CD45 CD45+ CD8+ Cell cell count cell counts cell-mediated response ChAdOx1 ChAdOx1 nCoV-19 changes in common common variable immunodeficiency common variable immunodeficiency (CVID) Control Coronavirus-2 COVID-19 infection cumulative cut-off value CVID decrease ELISPOT ELISpot assay evaluated except for flow cytometric healthy control healthy controls healthy individual healthy individuals humoral IFN-γ IFN-γ ELISPOT IFN-γ ELISpot assay IFN-γ producing T cells immune response immunodeficiency Immunoglobulin Immunoglobulin G immunosuppressive immunosuppressive therapy individual interferon interferon-γ Killer cell less Lymphocytes measure morbidity natural killer natural killer cell not different not significant Patient patients positive Primary Immunodeficiency producing protein S raised receiving response Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus-2 shown Side effects significant difference significant differences significantly significantly lower Specific statistically stem cell Stem cell transplantation T cell T cell response T cells tested therapy These data vaccination Vaccinations variable virus-specific T cell virus-specific T-cell with COVID-19 [DOI] 10.3389/fimmu.2022.907125 PMC 바로가기 [Article Type] Article
Data on immunogenicity and reactogenicity to COVID-19 vaccination among patients receiving maintenance dialysisData article Published on 2022-06-012022-10-05 Journal: Sensors (Basel, Switzerland) [Category] 변종, [키워드] acute respiratory syndrome assays cellular Cellular immune response Complete coronavirus coronavirus disease COVID-19 COVID-19 vaccination dialysis dose Effectiveness ELISPOT exclusion General population Hemodialysis homologous humoral immune response immune response Immunity immunoassay immunoglobulins increased risk interferon-γ Microparticle morbidity and mortality Patient Peritoneal dialysis produced reactogenicity receiving regimen SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 vaccine single dose T cells tested the vaccine trials vaccination [DOI] 10.1016/j.dib.2022.108271 [Article Type] Data article
Persistence of immune responses to the Sinopharm/BBIBP-CorV vaccineSinopharm/BBIBP-CorV 백신에 대한 면역 반응의 지속성Article Published on 2022-06-012022-09-11 Journal: Immunity, Inflammation and Disease [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, [키워드] ACE2 age all age groups angiotensin Angiotensin-converting enzyme antibody Antibody Response Antibody responses assays blocking antibodies Cell Cohort COVID-19 declined detectable determine Efficacy ELISPOT ELISpot assays enzyme enzyme-linked immunosorbent enzyme-linked immunosorbent assay Ex vivo group groups Hospitalization immune response immune responses Immunity individual individuals interferon gamma investigated Kinetics long term memory B memory B cell overlapping peptide peptides persistence Protein RBD receptor Receptor-binding domain remained response SARS-CoV-2 second dose severe disease Sinopharm Sinopharm/BBIBP-CorV Spike protein T cell T cell response T cell responses the RBD the receptor-binding domain the spike protein the vaccine total antibodies total antibody Vaccine Vaccines variants variants of concern virus were assessed were measured [DOI] 10.1002/iid3.621 PMC 바로가기 [Article Type] Article
Comparison between an in-house SARS-CoV-2 ELISpot and the T-Spot® Discovery SARS-CoV-2 for the assessment of T cell responses in prior SARS-CoV-2-infected individuals이전 SARS-CoV-2 감염자의 T 세포 반응 평가를 위한 사내 SARS-CoV-2 ELISpot과 T-Spot® Discovery SARS-CoV-2 간의 비교Article Published on 2022-06-012022-09-12 Journal: Journal of Clinical Virology [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] ELISPOT SARS-CoV-2 SARS-CoV-2-infected individual T cell response [DOI] 10.1016/j.jcv.2022.105158 PMC 바로가기 [Article Type] Article
Cellular and Humoral Immunity to SARS-CoV-2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease-Modifying Therapies: A Multi-Ethnic Observational StudyOcrelizumab 및 기타 질병 수정 요법을 사용하는 다발성 경화증 환자의 SARS-CoV-2 감염에 대한 세포 및 체액 면역: 다민족 관찰 연구Observational Study Published on 2022-06-012022-09-11 Journal: Annals of neurology [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료법, [키워드] age ANN antibody Antibody Response Antibody responses assays association Asymptomatic cellular Cellular and humoral immunity Cellular and humoral responses Cellular immune response chemiluminescence immunoassay Clinical course Clinical severity coronavirus disease Coronavirus disease 2019 correlated correlation COVID-19 determine domain Effect ELISA ELISPOT ELISpot assays enzyme-linked immunosorbent enzyme-linked immunosorbent assay evaluated Evidence evidence of group Hospitalized humoral Humoral and cellular immune responses Humoral immunity Humoral response humoral responses IFNγ IL-2 immune responses immunoassay immunologic response immunologic responses Infection Laboratory Live virus microneutralization MOST Multiple multiple sclerosis multivariate analyses Multivariate analysis N-terminal domain Natalizumab not differ Ocrelizumab Other Patient performed Protein RBD receptor recruited respiratory response SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 spike sclerosis Severe acute respiratory syndrome severity Spearman sphingosine spike Spike protein symptomatic infection T-cell Response T-cell responses therapy with COVID-19 [DOI] 10.1002/ana.26346 PMC 바로가기 [Article Type] Observational Study
Post-COVID-19 Fatigue and SARS-CoV-2 Specific Humoral and T-Cell Responses in Male and Female Outpatients남성 및 여성 외래 환자의 코로나19 이후 피로 및 SARS-CoV-2 특정 체액 및 T-세포 반응Article Published on 2022-05-262022-09-12 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] acute COVID-19 acute infection Analysis assessment both sexes Clinical characteristics conducted Course COVID-19 development disease ELISA ELISPOT enzyme-linked immunosorbent evaluate Ex vivo examined fatigue female Germany humoral IFN-γ IFNγ IgG antibody IL-2 individual Inflammation interferon-γ Level male median time men mild infection not differ Outpatient outpatients participant pathophysiological mechanism producing response SARS-CoV-2 SARS-CoV-2-specific T-cell response scale Serum level significantly significantly lower Specific suffered T-cell T-cell Response T-cells treated university were measured women [DOI] 10.3389/fimmu.2022.902140 PMC 바로가기 [Article Type] Article
Humoral, Cellular and Cytokine Immune Responses Against SARS-CoV-2 Variants in COVID-19 Convalescent and Confirmed Patients With Different Disease Severities다양한 질병 중증도를 가진 COVID-19 회복기 및 확인된 환자의 SARS-CoV-2 변이체에 대한 체액, 세포 및 사이토카인 면역 반응Article Published on 2022-05-172022-09-11 Journal: Frontiers in Cellular and Infection Microbiology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, [키워드] ADE Against Alpha alpha and delta variants Alpha variant Anti-RBD IgG cellular Cellular immune response cellular immunity chemokine chemokines Confirmed convalescent convalescent sera correlation COVID-19 Cytokines delta variant Delta variants disease disease severity ELISA ELISPOT evaluate exhibited fold greater humoral Humoral and cellular immune responses humoral immune response Humoral immunity IgG IL-6 immune immune response immune responses Immunity immunoassays individual Inflammatory mediators IP-10 MCP-1 mediators multiplex neutralization potency Neutralizing activity Omicron variant Omicron variants Patient patients performed pseudovirus pseudovirus infection quantified Raji cells RBD-specific IgG response risk SARS-CoV-1 SARS-CoV-2 SARS-CoV-2 pseudovirus infection SARS-CoV-2 variant SARS-CoV-2 variants serum severe disease Significant significantly specific antibodies spike-specific antibodies Spike-specific antibody T cell T cells variant virus was measured [DOI] 10.3389/fcimb.2022.862656 PMC 바로가기 [Article Type] Article
Fitness of B-Cell Responses to SARS-CoV-2 WT and Variants Up to One Year After Mild COVID-19 – A Comprehensive Analysis경증 COVID-19 이후 최대 1년까지 SARS-CoV-2 WT 및 변이체에 대한 B 세포 반응의 적합성 - 종합 분석Article Published on 2022-05-022022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료법, [키워드] Affinity maturation All participants Alpha Anti-RBD antibodies antibodies antibody Antibody Response Antibody responses Antibody titer Antibody titers Antigen antigen-specific memory B cells assays avidity B-cell binding binding antibodies binding antibody Comprehensive correlated COVID-19 declined Delta delta variant domain ELISA ELISPOT evaluate fitness Gamma IgA IgG memory B memory B cell memory B cells memory B-cell Mild N protein neutralization Neutralizing Neutralizing antibodies Neutralizing antibody titer neutralizing antibody titers Neutralizing titer neutralizing titers nucleocapsid participant plasmablast plasmablast responses plasmablasts post infection predicted Protein remained response SARS-CoV-2 SARS-CoV-2 specific memory B cells SARS-CoV-2 WT significantly increased symptomatic thiocyanate titers variant variants variants of concern waned were assessed were measured wild-type Year [DOI] 10.3389/fimmu.2022.841009 PMC 바로가기 [Article Type] Article